Brussels, 17 January 2023 – An Industry Advisory Group (IAG) representing biotechnology across sectors, countries and through the innovation pathway has been launched to support EuropaBio’s new Biomanufacturing Platform.
The IAG includes SMEs, mid and large sized companies, plus National associations, with the aim to ensure that biomanufacturing is recognised and supported as a significant part of Europe’s economic growth in a rapidly accelerating global biomanufacturing market.
The 2023 IAG includes:
- Audrey Bru, Lallemand (UK/FR)
- Inga Matijosyte, LBTA (LT)
- Matt Moran, IBEC (IRE)
- Sarah Moundir, Novartis (CH)
- Gwenaël Servant, Abolis (FR)
- Sabrina Spina, Olon (IT)
- Peter Steen Mortensen, Novozymes (DK)
- Tineke Van hooland, Bio.be (BE)
The IAG kick starts the Biomanufacturing Platform growth in 2023, with the Biomanufacturing Policy Summit hosted on March 15 in Brussels. The Group will ensure industry-relevant definitions, vision, case studies and recommendations to policy stakeholders at national and European level so that Europe is globally competitive.
Biomanufacturing is already present within most sectors, whether product or process-based, including advanced therapies such as cell and gene therapy, food, materials and industry intermediates. It provides significant employment and economic growth, as Europe strives to meet the Green Deal and deliver advanced healthcare particularly in response to unmet needs such as those within rare diseases.
Dr Virginia Claudio, EuropaBio Senior Adviser and Programme Manager said “Biomanufacturing investments are of paramount importance for EU tech sovereignty and quality of life of EU citizens. The IAG behind the Biomanufacturing Platform brings the voices of industry and economic development for Europe and will ensure that it is always at the forefront of Europe’s policy priorities.”